Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALT-IPF: Intravenous Delivery of Lung Spheroid Stem Cells in IPF
NCT04262167Phase 1Active, not recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2020
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Lung Spheroid Stem Cells in idiopathic pulmonary fibrosis (IPF) and progressive fibrotic interstitial lung disease (PF-ILD) (4 cohorts), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events at 24 months, Number of Participants With Hematological Parameters of Potential Clinical Importance at 24 months and 1 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
Lung Spheroid Stem Cells
03
Conditions
idiopathic pulmonary fibrosis (IPF)progressive fibrotic interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on NCT04262167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262167.